[Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
Through consensus, establish a post-marketing scheme and the technical processes to evaluate Chinese medicine's immunotoxicity on a population, as well as its beneficial influences on the immune system. Provide regulations on the collection, storage and transportation of serum samples. This article applies to the post-marketing scientific evaluation of the immunotoxicity of parenterally administered, and for other ways of taking Chinese medicine.
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yan-Ming
YM
Xie
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yu-Bin
YB
Zhao
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Jun-Jie
JJ
Jiang
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yan-Peng
YP
Chang
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Wen
W
Zhang
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Hao
H
Shen
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Peng-Fei
PF
Lu
D032921:Consensus; D004342:Drug Hypersensitivity / Q000209:etiology / Q000276:immunology*; D016903:Drug Monitoring / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D004365:Drugs, Chinese Herbal / Q000009:adverse effects*; D006801:Humans; D007158:Immunologic Techniques / Q000379:methods* / Q000592:standards; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000592:standards; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D004365:Drugs, Chinese Herbal